Cargando…
Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043945/ https://www.ncbi.nlm.nih.gov/pubmed/35446384 http://dx.doi.org/10.1182/bloodadvances.2022007185 |
| _version_ | 1784694997190180864 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9043945 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90439452022-04-28 Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016. Blood Adv Errata American Society of Hematology 2022-04-19 /pmc/articles/PMC9043945/ /pubmed/35446384 http://dx.doi.org/10.1182/bloodadvances.2022007185 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Errata Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016. |
| title | Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016. |
| title_full | Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016. |
| title_fullStr | Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016. |
| title_full_unstemmed | Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016. |
| title_short | Ferrari N, Ward G, Gewinner C, et al. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Adv. 2021;5(20):4003-4016. |
| title_sort | ferrari n, ward g, gewinner c, et al. antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for t-cell lymphoma. blood adv. 2021;5(20):4003-4016. |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043945/ https://www.ncbi.nlm.nih.gov/pubmed/35446384 http://dx.doi.org/10.1182/bloodadvances.2022007185 |